Market Newsdesk

Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.

Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated that the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and continued favorable overall tolerability, consistent with the safety outcomes observed in prior cohorts.

The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Meeting the primary safety and tolerability endpoint in this dose-escalation stage, including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD.

About Clearmind Medicine Inc.

Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND.”

For further information, visit: https://www.clearmindmedicine.com or contact:

Investor Relations
[email protected]
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

Adds Paul Davis Restoration and California Closets Company-Owned Operations in Key Midwest U.S. Markets

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) — FirstService Corporation (TSX and NASDAQ: FSV) (“FirstService”) today announced that it has completed two acquisitions which further add to the company-owned operations within its Paul Davis Restoration and California Closets business lines. Terms of the transactions were not disclosed.

Paul Davis Restoration recently expanded its company-owned platform with the acquisition of its franchised operation covering the Cleveland and Akron, Ohio markets. This business provides mitigation, contents, reconstruction and mold remediation services to residential property owners, as well as commercial and institutional accounts. The existing leadership team will retain an ownership interest and continue to run day-to-day operations across this Ohio region. This acquisition furthers our strategy of selectively acquiring franchises within our aggregate network of approximately 375 locations across North America.

California Closets acquired the franchised territories encompassing the metropolitan areas of Indianapolis, Indiana; Louisville and Lexington, Kentucky; and Cincinnati, Ohio. This acquisition further expands the owned operations of the California Closets brand into additional markets with significant future growth potential.

“We continue to advance our company-owned strategies at Paul Davis and California Closets as opportunities present themselves,” said Scott Patterson, CEO of FirstService. “These tuck-under acquisitions bolster our presence and ability to capitalize on the growth opportunities in major markets across North America,” he concluded.

ABOUT FIRSTSERVICE CORPORATION

FirstService Corporation is a North American leader in the property services sector, serving its customers through two industry-leading service platforms: FirstService Residential, North America’s largest manager of residential communities; and FirstService Brands, one of North America’s largest providers of essential property services delivered through individually branded company-owned operations and franchise systems.

FirstService generates approximately $5.5 billion in annual revenues and has more than 30,000 employees across North America. With significant insider ownership and an experienced management team, FirstService has a long-term track record of creating value and superior returns for shareholders. The Common Shares of FirstService trade on the NASDAQ and the Toronto Stock Exchange under the symbol “FSV”, and are included in the S&P/TSX 60 Index. More information is available at www.firstservice.com.

COMPANY CONTACTS:

Jeremy Rakusin

CFO

FirstService Corporation

(416) 960-9566

HAMBURG, Germany and AUSTIN, Texas, April 14, 2026 (GLOBE NEWSWIRE) — XCHG Limited (“XCharge” or the “Company”) (Nasdaq: XCH), an integrated EV charging and energy solutions company, today announced that it will participate in the Webull Corporate Connect Webinar Series for the Clean Energy Sector, to be held virtually on April 15, 2026.

Joel A. Gallo, Chief Financial Officer of XCharge, will discuss the Company’s financial performance, while Aatish Patel, Chief Operating Officer of XCharge, will present on operations and deployment strategy for high-power EV Charging infrastructure.

Details of the presentation are as follows:
Date and Time: Wednesday, April 15, 2026, at 1:00 PM ET
Presenters: Joel A. Gallo, Chief Financial Officer, and Aatish Patel, Chief Operating Officer
Registration Link: Here

About XCharge 

XCharge (NASDAQ: XCH), founded in 2015, is an integrated EV charging and energy solutions company. With dual headquarters in Hamburg, Germany and Austin, Texas, the Company offers comprehensive EV charging solutions, which primarily include the DC fast chargers and the advanced battery-integrated DC fast chargers as well as its accompanying services. Through the combination of XCharge’s proprietary charging technology, energy storage system technology and accompanying services, the Company enhances EV charging efficiency and unlocks the value of energy storage and management. Committed to providing innovative and efficient EV charging solutions, XCharge is actively working toward establishing a global green future that is critical to long-term growth and development.

About Webull Financial

Webull Financial is a leading online brokerage platform committed to empowering self-directed investors with innovative tools and cutting-edge technology. With low-cost trading on a wide range of assets, advanced charting tools, and real-time market data, Webull is revolutionizing the way individuals approach investing. The user-centric approach and commitment to staying at the forefront of industry trends underscore the mission to provide a seamless and rewarding experience for traders of all levels. Through the Webull Group, Webull Financial and its affiliates combine to serve tens of millions of users from over 180 countries worldwide. Securities and futures trading is offered to customers by Webull Financial LLC (“Webull Financial”), a broker-dealer registered with the Securities and Exchange Commission (SEC) and a futures commission merchant registered with the Commodity Futures Trading Commission (CFTC). Webull Financial is a member of the Financial Industry Authority (FINRA), the National Futures Association (NFA), and the Securities Investor Protection Corporation (SIPC). All investing is subject to risk, including the possible loss of principal. For more information about Webull, visit www.webull.com.

Safe Harbor Statement 

This press release contains forward-looking statements. Such statements are made pursuant the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Statements that are not historical facts, including statements about XCHG Limited’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties, and a number of factors could cause actual results to differ materially from those contained in any forward-looking statement. In some cases, forward-looking statements can be identified by words or phrases such as “may,” “will,” “expect,” “anticipate,” “objective,” “target,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. Further information regarding these and other risks, uncertainties or factors is included in XCHG Limited’s filings with the United States Securities and Exchange Commission.
All information provided in this press release is as of the date of this press release, and XCHG Limited does not undertake any duty to update such information, except as required under applicable law.

For investor and media inquiries, please contact:

XCharge
IR Department
Email: [email protected]

Water Tower Research Asia
Feifei Shen, CFA
Tel: +86 134-6656-6136
Email: [email protected]

Findings underpin the scientific rationale for Anavex’s targeted autophagy approach with orally administered blarcamesine

Convergence of impaired autophagy and synaptic dysfunction across neurodevelopmental and neurodegenerative conditions aligns with blarcamesine’s mechanism of action

These findings support Anavex’s intent to advance blarcamesine into pivotal clinical studies to further evaluate its potential in addressing unexpectedly common CNS disease mechanisms

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced new findings on the shared biology between autism spectrum disorder (ASD) and Alzheimer’s disease (AD), a core area of Anavex’ development plans with its autophagy enhancing orally administered blarcamesine.

Key Highlights

• Multiple peer-reviewed publications point to biological link between autism spectrum disorder (ASD) and Alzheimer’s disease (AD), including shared disruptions in autophagy.
• Epidemiological data show that autistic adults may be diagnosed with Alzheimer’s and related dementias at rates up to 8 times higher than the general population, with onset occurring years or decades earlier than typical.
• Converging human genetic evidence links numerous high-confidence ASD risk genes — including TSC1/TSC2, PTEN, SHANK3, and FMRP — to impaired cellular autophagy, establishing autophagy dysfunction as a shared molecular substrate across genetically diverse forms of ASD.
• Synaptic dysfunction in ASD is now understood to arise, in substantial part, from a failure of autophagy-dependent synaptic pruning — causing an excess of poorly regulated synaptic connections and disrupted excitatory–inhibitory balance in neural circuits.
• The brain’s extracellular matrix (ECM) is pathologically altered in ASD and is bidirectionally coupled to autophagy.
• Restoration of autophagy impairment, now emerging as a central shared pathway in both ASD and AD, is precisely the biological system targeted by blarcamesine through its activation of SIGMAR1.
• Blarcamesine has demonstrated restoration of autophagy through SIGMAR1 activation in preclinical models and has shown clinical effects in Phase IIb/III trials in early Alzheimer’s disease, Phase II/III in Rett syndrome (a neurodevelopmental disorder caused by MECP2 mutation), and Phase II in Parkinson’s disease dementia.
• Collectively, these data provide a scientific basis for advancing blarcamesine into pivotal clinical studies, subject to further evaluation and regulatory considerations.

Reframing Brain Disorders: Converging Pathways in Neurodevelopment and Neurodegeneration

For decades, autism and Alzheimer’s disease were treated as conditions on opposite ends of the lifespan — one affecting brain development in early childhood, the other driving decline in old age. New research is adding a critical new twist. A landmark April 2025 study published in JAMA analyzed Medicare and Medicaid records covering more than 114,000 autistic adults and found that dementia prevalence among this population was dramatically elevated compared to the general population.¹ A separate recent 2026 paper in Frontiers in Neuroscience identified convergent disruptions in two critical systems shared by both conditions: The autophagy network and the synaptic regulation machinery.²

Autophagy is the cell’s natural process for clearing misfolded proteins, damaged organelles, lipids, and other cellular waste. In autism, excess synaptic connections form which are not properly pruned during development. In Alzheimer’s disease, impaired autophagy, worsened by ApoE4 lipoproteins, allows toxic protein aggregates — including amyloid-beta and fibrillary tau — to accumulate unchecked. Both conditions, in essence, share a common driver of disease pathogenesis: A failure of the brain’s housekeeping system.

Synaptic Dysfunction in ASD: When the Brain’s Pruning Mechanism Fails

The human brain is sculpted by a process of exuberant synapse formation followed by selective elimination — synaptic pruning — that removes excess connections and renders neural circuits fully functional. Autophagy is a core cellular mechanism enabling this pruning. A landmark Neuron study³ found excess dendritic spines in postmortem ASD cortical tissue compared to controls — direct evidence of failed pruning correlating with impaired autophagy. Blocking neural autophagy genetically reproduced core ASD features: Excess synapse density, impaired social behavior, and repetitive behaviors; restoring autophagy normalized both synaptic architecture and behavior. Microglia, the brain’s resident immune cells, depend equally on autophagy for synapse elimination.⁴ The downstream consequence of both failures is a disruption of excitatory–inhibitory balance — a core pathobiological signature of ASD.⁵^,⁶

The Genetic Architecture of ASD Converges on Autophagy

ASD is genetically heterogeneous, yet genome analyses repeatedly converge on a common theme: Mutations and copy-number variants in genes whose protein products regulate autophagy. Among the most studied are mutations in TSC1/TSC2 and PTEN genes, whose loss of function suppresses autophagy and is associated with high rates of ASD alongside epilepsy and intellectual disability.⁷ Fragile-X syndrome — the most common inherited cause of intellectual disability and autism — likewise involves reduced autophagic flux in hippocampal neurons, with activation of autophagy rescuing aberrant spine morphology, synaptic plasticity, and cognition in preclinical models.⁵ SHANK3 mutations further alter autophagy-dependent protein homeostasis at the synapse.⁸ Whole-exome sequencing has additionally identified copy-number variants in core autophagy genes in sporadic ASD cases.⁹ This genetic convergence is not coincidental; it is pathobiologically instructive.

The Brain’s Extracellular Matrix and Autophagy: A Bidirectional Relationship

A third dimension of ASD biology is receiving growing attention: The extracellular matrix (ECM) — the structural scaffold of proteins and proteoglycans surrounding all brain cells. Its most specialized form, the perineuronal net (PNN), enwraps key inhibitory interneurons and governs critical-period synaptic plasticity and circuit stability.¹⁰ PNN architecture is consistently altered in genetic ASD mouse models and in postmortem human ASD brain tissue.¹¹^,¹² The ECM and autophagy are bidirectionally coupled: The ECM modulates intracellular autophagic activity, while autophagic flux is required for normal ECM remodeling and synaptic structural integrity.¹³^,¹⁴^,¹⁵ PNN disruption has also been identified as relevant for Alzheimer’s disease,¹⁶ reinforcing that the brain’s ECM is not a passive structural scaffold but an active participant in the same homeostatic networks that autophagy governs — and that blarcamesine targets through SIGMAR1 activation.

Why This Matters for Anavex and Blarcamesine

Blarcamesine is an investigational oral therapy that activates SIGMAR1, a key intracellular chaperone protein that sits at a critical junction of cellular homeostasis. Peer-reviewed research has established that SIGMAR1 activation by blarcamesine restores impaired autophagy by stimulating ULK1 phosphorylation — a central signaling node that initiates the formation of autophagosomes, the cellular organelles responsible for engulfing and recycling damaged proteins and organelles.

This mechanism was first demonstrated at the molecular level in a 2019 publication in Cells, which showed that blarcamesine enhances autophagic flux in human cells and increases proteostasis capacity in the roundworm C. elegans, ultimately rescuing the organism from paralysis caused by protein aggregation.¹⁷ A 2025 iScience publication further elucidated the molecular protein binding mechanism of blarcamesine to SIGMAR1 and GABARAP, a core autophagy protein.¹⁸

The emerging picture of ASD — as a condition with co-contribution of autophagy failure, synaptic pruning deficits, convergent genetic disruption of protein homeostasis pathways, and ECM dysregulation — maps directly onto the disease biology that blarcamesine is designed to address. The therapeutic rationale is not inferential; it is mechanistically grounded in the same autophagic machinery that blarcamesine has been shown to restore across multiple model systems and in human clinical trials.

Clinical Evidence Across the Lifespan

Anavex’s clinical development program spans both neurodegenerative and neurodevelopmental conditions, reflecting precisely the kind of cross-lifespan therapeutic strategy that the emerging autism–Alzheimer’s research now suggests is needed:

Alzheimer’s Disease: In the Phase IIb/III ANAVEX^®2-73-AD-004 trial, once-daily oral blarcamesine significantly slowed cognitive and functional decline in patients with early Alzheimer’s disease over 48 weeks, supported by biomarker evidence including improved plasma Aβ42/40 ratio and significant reduction in brain atrophy in key brain areas. A precision medicine approach demonstrated that patients carrying wild-type SIGMAR1 (the ABCLEAR1 population, representing approximately 70% of the global population) showed enhanced clinical responses. This approach was further amplified in the ABCLEAR3 population, including the brain’s extracellular matrix (ECM) wild-type protein COL24A1.

Rett Syndrome: The AVATAR trial demonstrated clinical effects in adult patients with Rett syndrome, a severe neurodevelopmental disorder caused by mutations in the MECP2 gene — one of the genes now identified as key for brain development. Treatment was associated with changes in disease-relevant biomarkers, including a significant increase in GABA levels. Open-label extension data indicated disease-modifying effects. A Phase II/III pediatric trial (EXCELLENCE) has also been completed.

Parkinson’s Disease Dementia: Blarcamesine has shown proof-of-concept efficacy in a Phase II study in Parkinson’s disease dementia, a condition also linked to impaired autophagy and protein aggregation (alpha-synuclein). Advanced clinical development in Parkinson’s disease is ongoing.

“The growing recognition that neurodevelopmental and neurodegenerative conditions share fundamental disease biology — particularly around autophagy — validates the foundational science behind Anavex’s platform,” said Wolfgang Liedtke, MD, PhD, Senior Vice President and Global Head of Neurology at Anavex. “We are looking forward to proceeding with pivotal clinical trials on the principle that restoring cellular homeostasis through SIGMAR1 activation may address disease biology across the CNS, from childhood through old age.”

“As independent researchers from institutions including Mount Sinai, Boston University, Drexel University, and the Karolinska Institute continue to map the molecular connections between autism and Alzheimer’s, the therapeutic rationale for a precision medicine approach targeting autophagy with blarcamesine has never been more encouraging,” said Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex. “Anavex’s unique precision medicine approach recognizes autophagy dysfunction as a common upstream contributor preceding diverse downstream pathologies across the age spectrum.”

This release discusses investigational uses of an agent in development and is not intended to convey conclusions about efficacy or safety. There is no guarantee that any investigational uses of such product will successfully complete clinical development or gain health authority approval.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer’s disease, Parkinson’s disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex’s lead drug candidate, blarcamesine (ANAVEX^®2-73), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer’s disease, a Phase 2 proof-of-concept study in Parkinson’s disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. Blarcamesine is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. Blarcamesine also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop blarcamesine for the treatment of Parkinson’s disease. We believe that ANAVEX^®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX^®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter,Facebook, Instagram, and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: [email protected]

Investors:

Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: [email protected]

References

1. Vivanti G et al. “Prevalence of Dementia Among US Adults With Autism Spectrum Disorder.” JAMA Network Open. 2025;8(1):e2453691.
2. Phillips WT et al. “Pathophysiologic similarities between autism spectrum disorder and Alzheimer’s disease: therapeutic possibilities.” Frontiers in Neuroscience. 2026;19:1737007.
3. Tang G et al. “Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits.” Neuron. 2014;83(5):1131–1143.
4. Kim HJ et al. “Deficient autophagy in microglia impairs synaptic pruning and causes social behavioral defects.” Molecular Psychiatry. 2017;22(11):1576–1584.
5. Yan J et al. “Activation of autophagy rescues synaptic and cognitive deficits in fragile X mice.” PNAS. 2018;115(41):E9707–E9716.
6. Hui KK et al. “GABARAPs dysfunction by autophagy deficiency in adolescent brain impairs GABA₁ receptor trafficking and social behavior.” Sci Adv. 2019;5(4):eaau8237.
7. Kwon CH et al. “Pten regulates neuronal arborization and social interaction in mice.” Neuron. 2006;50(3):377–388.
8. Bourgeron T. “A synaptic trek to autism.” Curr Opin Neurobiol. 2009;19(2):231–234.
9. Dere E et al. “Heterozygous ambra1 deficiency in mice: a genetic trait with autism-like behavior restricted to the female gender.” Front Behav Neurosci. 2014;8:181.
10. Fawcett JW et al. “The roles of perineuronal nets and the perinodal extracellular matrix in neuronal function.” Nat Rev Neurosci. 2019;20(8):451–465.
11. Burket JA et al. “Region-Specific Alterations of Perineuronal Net Expression in Postmortem Autism Brain Tissue.” Front Psychiatry. 2022;13:872615.
12. Adeyelu TT et al. “Behavioral regulation by perineuronal nets in the prefrontal cortex of the CNTNAP2 mouse model of autism spectrum disorder.” Front Behav Neurosci. 2023;17:1114789.
13. Fung C et al. “Induction of Autophagy during Extracellular Matrix Detachment Promotes Cell Survival.” Mol Biol Cell. 2008;19(3):797–806.
14. Bhatt DL et al. “Cooperation of cell adhesion and autophagy in the brain: Functional roles in development and neurodegenerative disease.” Autophagy Reports. 2021;1(1):192–222.
15. Iozzo RV et al. “Instructive Roles of Extracellular Matrix on Autophagy.” Mol Cell Biol. 2014;34(22):4001–4012.
16. Vries LE et al. “Resilience to Alzheimer’s disease associates with alterations in perineuronal nets.” Alzheimer’s & Dementia. 2025.
17. Christ MG et al. “Sigma-1 receptor activation induces autophagy and increases proteostasis capacity in vitro and in vivo.” Cells. 2019;8(3):211.
18. Baeken MW et al. “Conserved LIR-specific interaction of Sigma-1 receptor and GABARAP.” iScience. 2025;28(9):113287.

TORONTO, April 14, 2026 (GLOBE NEWSWIRE) — Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the 2026 Bloom Burton & Co. Healthcare Investor Conference on Wednesday, April 22, 2026 at 10:00 a.m. Eastern Time at the Metro Toronto Convention Centre.

The presentation will be broadcast live and archived on the Company’s website at www.profoundmedical.com under “IR Calendar” in the Investors section.

About Profound Medical Corp.

Profound is a commercial-stage medical device company and an innovator in interventional MRI procedures, enabling precise, incision-free therapies that improve clinical confidence, procedural control, and patient outcomes. By leveraging real-time MRI guidance, Profound’s technologies are designed to replace uncertainty with clarity across treatment planning, delivery, and confirmation.

The company’s flagship platform, TULSA-PRO^®, enables MRI-guided, incision-free prostate therapy designed for precision and flexibility. The TULSA Procedure™ allows physicians to see, treat, and confirm therapy in real time, supporting personalized treatment strategies across the continuum of prostate care—from whole-gland to subtotal, hemi, multifocal, and focal treatment. This approach enables individualized care for the full spectrum of prostate disease, including prostate cancer and/or benign prostatic hyperplasia (BPH), while minimizing side effects typically associated with surgery or radiation, such as urinary incontinence and/or erectile dysfunction.

Profound also commercializes Sonalleve^®, an MRI-guided therapy that provides a non-surgical treatment option for pain palliation of bone metastases, desmoid tumors, and osteoid osteoma, as well as for common gynecologic conditions including uterine fibroids and adenomyosis. Sonalleve delivers targeted therapy with no incisions, no blood loss during the procedure, no overnight hospital stay, and faster recovery — and, in gynecologic applications, enables uterine-sparing treatment that may help preserve fertility. Profound is also exploring additional clinical applications for Sonalleve, including non-invasive ablation of abdominal cancers and hyperthermia-based cancer therapies.

Profound Medical’s technologies are approved across major global markets. TULSA-PRO is cleared or approved in the United States, Europe, Canada, Saudi Arabia, India, Australia/New Zealand, and the UAE, while Sonalleve is cleared or approved in the United States (HDE), Europe, Canada, China, and Saudi Arabia.

Through real-time MRI guidance and data-driven innovation, Profound is advancing the future of MRI-guided therapy — expanding access to precise, personalized, and incision-free treatment options worldwide.

For further information, please contact:

Stephen Kilmer
Investor Relations
[email protected]
T: 647.872.4849

FDA assigned PDUFA target action date of January 29, 2027

No advisory committee meeting expected

BOSTON, April 14, 2026 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for ulixacaltamide HCl for the treatment of essential tremor (ET) in adults. The FDA has set a target action date under the Prescription Drug User Fee Act (PDUFA) of January 29, 2027 and is not planning to hold an advisory committee meeting.

“Today’s announcement brings us one step closer to delivering something patients living with essential tremor have been waiting for, a therapy developed specifically for their condition,” said Marcio Souza, president and chief executive officer. “We look forward to continuing to work with the FDA through the review process while we prepare for the commercial launch.”

Ulixacaltamide for treatment of essential tremor 

The NDA is supported by positive results from the Essential3 Phase 3 program, which comprised two simultaneously enrolled pivotal studies in adults with essential tremor. The statistically and clinically significant results from the Essential3 program provide the primary evidence of effectiveness for the NDA submission. Ulixacaltamide was generally well tolerated, with a safety profile consistent with previous trials and no drug-related serious adverse events. Ulixacaltamide received Breakthrough Therapy Designation (BTD) from the FDA in December 2025.

About Ulixacaltamide

Ulixacaltamide is a differentiated and highly selective small molecule inhibitor of T-type calcium channels designed to block abnormal neuronal burst firing in the Cerebello-Thalamo-Cortical (CTC) circuit correlated with tremor activity. Ulixacaltamide has received Breakthrough Therapy Designation from the FDA and is the most advanced program within Praxis’ Cerebrum™ small molecule platform.

About Praxis 
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and X/Twitter. 

Forward-Looking Statements 
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws, including express or implied statements regarding Praxis’ future expectations, plans and prospects, including, without limitation, statements regarding the anticipated timing of clinical trials, the anticipated timing of regulatory submissions and interactions and potential market opportunity and commercial potential of Praxis’ product candidates, as well as other statements containing the words “anticipate,” “believe,” “continue,” “could,” “endeavor,” “estimate,” “expect,” “anticipate,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “target,” “will” or “would” and similar expressions that constitute forward-looking statements under the Private Securities Litigation Reform Act of 1995. 

The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical trials; the expected timing of clinical trials, data readouts and the results thereof, and submissions for regulatory approval or review by governmental authorities; regulatory approvals to conduct trials; and other risks concerning Praxis’ programs and operations as described in its Annual Report on Form 10-K for the year ended December 31, 2025 and other filings made with the Securities and Exchange Commission. Although Praxis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on information and factors currently known by Praxis. As a result, you are cautioned not to rely on these forward-looking statements. Any forward-looking statement made in this press release speaks only as of the date on which it is made. Praxis undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise.

FORT WORTH, TX, April 14, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company”, “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market, announced today that it will report its first quarter 2026 financial results on Tuesday, May 12, 2026 before the U.S. financial markets open.

The Company will host a conference call and webcast on May 12, 2026 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2026 and hold a question and answer session at the end of the call. The toll-free number to call for this teleconference is 888-506-0062 (international callers: 973-528-0011) and the access code is 931324. A telephonic replay of the conference call will be available through Tuesday, May 26, 2026, by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 53818.

A live webcast of Sanara’s conference call is accessible by clicking here and will be made available under the ”Events” section of the Company’s Investor Relations website, https://ir.sanaramedtech.com/. An online replay will be available for approximately one year following the conclusion of the live broadcast.

About Sanara MedTech Inc.

Sanara MedTech Inc. is a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical market. The Company develops, markets and distributes surgical products to surgeons at hospitals and surgical centers. Each of the Company’s products and technologies are designed to achieve the goal of providing better clinical outcomes at a lower overall cost for patients. Sanara’s products are primarily sold in the North American surgical tissue repair market. Sanara markets and distributes CellerateRX^® Surgical Activated Collagen^® Powder, BIASURGE^® Advanced Surgical Solution, FORTIFY TRG^® Tissue Repair Graft and FORTIFY FLOWABLE^® Extracellular Matrix, as well as a portfolio of advanced biologic products including: ACTIGEN^® Verified Inductive Bone Matrix, ALLOCYTE^® Plus Advanced Viable Bone Matrix, BiFORM^® Bioactive Moldable Matrix and TEXAGEN^® Amniotic Membrane Allograft to the surgical market. The Company believes it can drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. The Company strives to be one of the most innovative and comprehensive providers of effective surgical solutions and is continually seeking to expand its offerings for patients requiring treatments in the United States. For more information, please visit SanaraMedTech.com.

Investor Relations Contact:

Jack Powell or Mike Piccinino, CFA
ICR Healthcare
[email protected]